ESMO-GI 2017 - 19th World Congress on Gastrointestinal Cancer
Jun 28 - Jul 01, 2017 | BarcelonaSpain
LARVOL is not affiliated with 19th World Congress on Gastrointestinal Cancer and all trademarks, logos, and brand names are property of their respective owners
Showing 36 abstracts linked to Trials
A multi-cohort phase 1 study of ramucirumab plus durvalumab: Preliminary safety and clinical activity in patients with locally advanced and unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
Tumor Hyaluronan May Predict Benefit From PEGPH20 When Added to nab Paclitaxel/Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDA)
RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC)
Characteristics and response outcomes of long-term survivors in studies of first-line panitumumab for metastatic colorectal cancer
PEGPH20 improves pfs in patients with metastatic pancreatic ductal adenocarcinoma: A randomized phase 2 study in combination with nab-paclitaxel/gemcitabine
Baseline carcinoembryonic antigen predicts response to IMM-101 in advanced pancreatic cancer: Data analysis from a randomised, open label, phase II study
Nivolumab monotherapy in patients with advanced gastric or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: Sub-analysis of the CheckMate 032 study
Randomized, controlled phase III trial comparing 3D and 2D laparoscopic gastrectomy for gastric cancer
Efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma analyzed by patient age: A sub-analysis of the CheckMate 040 study
Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment
Prognostic and predictive role of neutrophils/lymphocytes ratio in metastatic colorectal cancer: A retrospective analysis of the TRIBE study by Gono
Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study
Central evaluation for surgical treatment options in FIRE-3- updated results and impact on overall Survival
A phase II study of FOLFOXIRI with bevacizumab in untreated metastatic colorectal cancer patients: A UGT1A1 genotype and safety results (QUATTRO study)
Rechallenge with cetuximab + irinotecan in 3rd-line in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients with acquired resistance to 1st-line cetuximab+irinotecan: The phase II CRICKET study by GONO.